Jérôme Verony
Articles
Zogenix Is Far Riskier Than Meets The Eye
Minerva Neurosciences: A Lacklustre Proposition All Around
Intercept And The Clinical Reality Of Treating NASH Fibrosis
Healing The World One Biotech Investment At A Time With Jerome Verony (Podcast)
AXS-05 Data Could Benefit MDD Patients While Leaving Axsome Shareholders Aching
What The Sage-217 Results In PPD Mean For Marinus
Bristol-Myers Squibb's Bid To Swallow Celgene Is A Bane For An Overcrowded Oncology Space
Keeping Focused Amidst The Biotech Bear
Marinus Is Aiming For The Gold Standard In PPD
Emboldened By Sage's Zulresso Slip, Marinus Is Set To Succeed In PPD And Orphan Epilepsy
Viking Therapeutics Won't Live Up To The Hype
CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX-2009
Does Achaogen Have The Operational Runway Required To Deliver Value?
Denali Follows Up First-Mover Advantage In LRRK2 With Sanofi Deal To Evaluate RIPK1 Inhibitors
Achaogen's Zemdri: Blockbuster Potential For A Pittance
Denali's Transport Vehicle Platform Holds Promise Beyond Neurodegenerative Disease
Actinium Pharmaceuticals: Neglected Assets In Niche Oncology
Achaogen: Contrarian Play At An Inflection Point
Marinus Pharmaceuticals - Be Greedy When Others Are Fearful
CytomX - Augmenting Antibodies Across Indications
2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?
Zymeworks - Protein Proficiency At A Discount
Biotech: The Tide Is Turning
Biotechs: Not So 'Darn Scary' After All - An SA Marketplace Roundtable
Introducing Second-Level Investing: The Reference For Discerning Life Sciences Investors
Sage's PhIII Success In PPD: What It Means For Marinus Pharmaceuticals
Marinus Pharmaceuticals: The Next Big Thing In CNS
SA Interview: Biotech Investing With Jérôme Verony
Marinus Pharmaceuticals: A Discarded CNS Gem Ready To Shine In 2017
Commercial Prospects For Plazomicin: An Expert's Take
Achaogen: Birth Of A Biotech Powerhouse
Achaogen: An Emerging Opportunity In The AMR Space